Brevibloc Ultra-short-acting β₁-selective blocker The beta-blocker to choose when reversibility matters. With a half-life of 9 minutes and the effect…

Emconcor Emconcor CHF Bisoprolol Krka Bisoprolol Teva Highly selective β₁-blocker The most β₁-selective of the routinely used beta-blockers, with documented mortality benefit…

…no AV block, and no clinically significant negative inotropy, making it combinable with beta-blockers. The price of pure vasodilatation is dependent oedema, which is…

…and intravenous diltiazem require a named-patient licence. Verapamil or a beta-blocker is therefore the practical first choice for rate control in this setting.

…ten minutes through hepatic glycogenolysis. In beta-blocker intoxication, glucagon is instead an inotrope that bypasses the blocked beta receptor, and the doses are five…

…unsuitable as first-line treatment in hypertensive crisis — but useful in pre-eclampsia and as afterload relief in combination with a nitrate and beta-blocker.

Kåvepenin Tikacillin Fenoximetylpenicillin EQL Pharma Narrow-spectrum beta-lactam antibiotic The first-choice oral penicillin for the most common respiratory and skin infections in outpatient…

…staphylococcal penicillin The beta-lactamase-stable penicillin and accordingly the first-line choice for skin and soft tissue infections where Staphylococcus aureus is the likely…

Doxyferm Doxycyklin EQL Pharma Vibranord Broad-spectrum tetracycline The tetracycline that covers both respiratory pathogens and the intracellular organisms that beta-lactams miss — Mycoplasma pneumoniae…

…potassium by a tenth of a millimole. Insulin-glucose, beta-agonists, and dialysis must be started in parallel, otherwise the arrhythmia risk returns when the…

…that increases renal perfusion while blood pressure falls. A selective D1 agonist without alpha or beta effects, with onset within minutes and duration under one…

…is ineffective. Its place in treatment is the symptomatic patient with HFrEF who remains above 70 beats per minute despite maximally tolerated beta-blockade, where…